Výsledky vyhledávání - "Jma van Gerven"

Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers

Autor: S Brooks, RGJA Zuiker, C Bleys, D Ziagkos, JA Moyer, L van Nueten, P Bonaventure, WC Drevets, JMA van Gerven, G Salvadore, GE Jacobs

Publikováno v: Journal of Psychopharmacology. :026988112311679

Background: Up to 40% of patients suffering from anxiety disorders do not benefit from currently available pharmacological treatments. Overactivity of the orexin-1 receptor (OX1R) has been implicated in anxiety- and panic-related states. Aim & method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25c7c5bfbba9c0f9e4ab37eed1043a6d
https://doi.org/10.1177/02698811231167989

Zobrazit plný text záznamu

Effect of intrapulmonary tetrahydrocannabinol administration in humans

Autor: Rik C. Schoemaker, J. den Hartigh, Adam F. Cohen, Jean-Louis Pinquier, Lineke Zuurman, Jcme Bender, Arno Hazekamp, C. Roy, Robert Verpoorte, Jma van Gerven

Publikováno v: Journal of Psychopharmacology. 22:707-716

This randomised, double-blind, placebo-controlled, cross-over study was designed to identify which pharmacodynamic parameters most accurately quantify the effects of delta-9-Tetrahydrocannabinol (THC), the predominantly psychoactive component of cann

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d09391209e66360cfd361c42abdfa0f
https://doi.org/10.1177/0269881108089581

Zobrazit plný text záznamu

Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron

Autor: Gabriel E. Jacobs, Imc Kamerling, J. van Pelt, Frans G. Zitman, Jma van Gerven, Roel H. DeRijk, ML de Kam

Publikováno v: Journal of Psychopharmacology, 24(1), 65-72

A recently developed oral serotonergic challenge test consisting of 5-Hydroxytryptophane (5-HTP, 200 mg) combined with carbidopa (CBD, 100 mg + 50 mg) exhibited dose-related neuroendocrine responsiveness and predictable pharmacokinetics. However, its

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3483a5e10a324cdfa72ae94e881ae10
https://doi.org/10.1177/0269881108094299

Zobrazit plný text záznamu

Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers

Autor: Jma van Gerven, Adam F. Cohen, HJ Kleijn, ML de Kam, Pccm Passier, Lineke Zuurman

Publikováno v: Journal of Psychopharmacology. 23:633-644

Abstract CB1/CB2 agonists are reported to have sedative, amnestic, analgesic and anti-emetic properties, which would make them ideal drugs for outpatient treatments under conscious sedation. The main objective of this in human study was to assess the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4889cc0c5d4577a2dbeffddbdd100f20
https://doi.org/10.1177/0269881108091551

Zobrazit plný text záznamu

Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa

Autor: R.H. de Rijk, J. P. Van Der Post, Gabriel E. Jacobs, Rik C. Schoemaker, J. van Pelt, Dhm Hoeberechts-Lefrandt, Ljca Smarius, ML de Kam, Jma van Gerven, Harm J. Gijsman, Frans G. Zitman

Publikováno v: Journal of Psychopharmacology. 22:426-433

5-hydroxytryptophan (5-HTP) is a direct 5-hydroxytryptamine (5-HT) precursor used to assess central serotonergic function. Its use has been limited by a narrow window between neuroendocrine changes and side effects, and variable kinetics related to i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898aa52ce437aa8cd14b418ae47669ea
https://doi.org/10.1177/0269881107082025

Zobrazit plný text záznamu

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol

Autor: Rwm Zoethout, Adam F. Cohen, K Van Dyck, Rik C. Schoemaker, M De Smet, SL de Haas, Keith Gottesdiener, Laura B. Rosen, M. G Murphy, Jma van Gerven

Publikováno v: Journal of Psychopharmacology, 26(2), 282-91
Journal of Psychopharmacology, 26(2), 282-291

Essential tremor (ET) is a relatively frequent neurological disorder that responds in some patients to gamma-aminobutyric acid A (GABAA) agonists such as the benzodiazepines. Partial subtype-selective GABAA agonists may have an improved side effect p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2424821892ee6db823ed48ff5e13f25
http://hdl.handle.net/1887/118587

Zobrazit plný text záznamu

Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state

Autor: A Andorn, Erica S. Klaassen, Paolo Fina, L Iavarone, Jma van Gerven, Msg Bani, Rwm Zoethout, E.T. te Beek

Publikováno v: Journal of Psychopharmacology, 26(2), 303-314

GSK598809 is a novel selective dopamine D3 receptor antagonist, currently in development for the treatment of substance abuse and addiction. In a blinded, randomized, placebo-controlled study, effects of single oral doses of 175 mg GSK598809 were eva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6e63ca9f63a0803d2508cfbc7c9915
https://pubmed.ncbi.nlm.nih.gov/22219221

Zobrazit plný text záznamu

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects

Autor: Mark E. Schmidt, Rwm Zoethout, Marieke Liem-Moolenaar, Jma van Gerven, P. De Boer, ML de Kam, Adam F. Cohen, Kari L. Franson

Publikováno v: Journal of psychopharmacology (Oxford, England). 24(11)

In this study the effects of R213129, a selective glycine transporter 1 inhibitor, on central nervous system function were investigated in healthy males in the absence and presence of scopolamine. This was a double-blind, placebo-controlled, 4-period

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c5c47395bfa4719c5b2574888818780
https://pubmed.ncbi.nlm.nih.gov/20142308

Zobrazit plný text záznamu

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol

Autor: Jaj Schmitt, S. J. De Visser, Marieke Liem-Moolenaar, Adam F. Cohen, Kari L. Franson, Jma van Gerven, Rik C. Schoemaker, Frank A Gray

Publikováno v: Journal of Psychopharmacology, 24(1), 73-82

Central Nervous System (CNS) effects of talnetant, an NK-3 antagonist in development for schizophrenia, were compared to those of haloperidol and placebo. The study was randomised, double-blind, three-way crossover of talnetant 200 mg, haloperidol 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdaae5283614134054a075cc75a117f7
https://hdl.handle.net/1887/119182

Zobrazit plný text záznamu

Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study

Autor: Rik C. Schoemaker, J.G. van Dijk, Maarten J. Titulaer, ML de Kam, Jma van Gerven, Jan J.G.M. Verschuuren, Paul W. Wirtz, UR Tjaden, Jgc van Hasselt, J. den Hartigh

Publikováno v: Clinical pharmacology and therapeutics. 86(1)

3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination. 3,4-Diaminopyridine enhances the release of acetylcholine at the neuromuscular synapse, and pyridostigmine inhib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d368c755763af626b597397680ffe87
https://pubmed.ncbi.nlm.nih.gov/19357643

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání